Intervacc

Intervacc AB (publ), a growth company in veterinary medicine with its vaccine Strangvac registered in 16 European countries, today announces participation in an international Healthcare conference:

Swiss Nordic Bio Conference 2026
Location: Radisson Blue Hotel, Zurich Airport
Format: Presentation and 1-on-1
Participation date: October 1
Participant: Carl-Johan Dalsgaard, CEO

For more information please contact:

Carl-Johan Dalsgaard, VD
Phone: +46 (0)8 120 10 600

E-mail: carl-johan.dalsgaard@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on September 15, 2026 at 08.30 CET.

About Strangvac

Strangvac is a vaccine against the severe disease equine strangles. The vaccine is approved for sales and marketing in the EU as well as the UK, Iceland, Norway and Liechtenstein, and has been launched in Sweden, Denmark, Finland, the UK, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.

About Intervacc

Intervacc AB is an animal health group that develops vaccines for animals. The company’s vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, visit intervacc.se

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10